

Peter D Friedmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8897323/publications.pdf>

Version: 2024-02-01

63
papers

2,695
citations

172457

29
h-index

182427

51
g-index

66
all docs

66
docs citations

66
times ranked

2270
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. <i>New England Journal of Medicine</i> , 2016, 374, 1232-1242.	27.0	255
2	Screening and intervention for alcohol problems. <i>Journal of General Internal Medicine</i> , 2000, 15, 84-91.	2.6	215
3	Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers, and Intentions. <i>Substance Abuse</i> , 2012, 33, 9-18.	2.3	179
4	Evidence-based treatment practices for drug-involved adults in the criminal justice system. <i>Journal of Substance Abuse Treatment</i> , 2007, 32, 267-277.	2.8	148
5	Alcohol Use in Adults. <i>New England Journal of Medicine</i> , 2013, 368, 365-373.	27.0	119
6	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , 2018, 91, 57-68.	2.8	114
7	Attitudes and Practices Regarding the Use of Methadone in US State and Federal Prisons. <i>Journal of Urban Health</i> , 2005, 82, 411-419.	3.6	107
8	Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications. <i>Health Affairs</i> , 2016, 35, 2289-2296.	5.2	89
9	Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform. <i>Health Affairs</i> , 2015, 34, 828-835.	5.2	86
10	Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 49-55.	2.8	86
11	A Randomized Trial of Methadone Initiation Prior to Release from Incarceration. <i>Substance Abuse</i> , 2012, 33, 19-29.	2.3	73
12	Accessibility of Addiction Treatment: Results from a National Survey of Outpatient Substance Abuse Treatment Organizations. <i>Health Services Research</i> , 2003, 38, 887-903.	2.0	70
13	Effect of an Organizational Linkage Intervention on Staff Perceptions of Medication-Assisted Treatment and Referral Intentions in Community Corrections. <i>Journal of Substance Abuse Treatment</i> , 2015, 50, 50-58.	2.8	67
14	The Affordable Care Act Transformation of Substance Use Disorder Treatment. <i>American Journal of Public Health</i> , 2017, 107, 31-32.	2.7	61
15	Initiation of buprenorphine during incarceration and retention in treatment upon release. <i>Journal of Substance Abuse Treatment</i> , 2013, 45, 222-226.	2.8	57
16	Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. <i>Neurotherapeutics</i> , 2020, 17, 55-69.	4.4	57
17	Integration of Substance Abuse Treatment Organizations into Accountable Care Organizations: Results from a National Survey. <i>Journal of Health Politics, Policy and Law</i> , 2015, 40, 797-819.	1.9	56
18	Trends in comprehensive service availability in outpatient drug abuse treatment. <i>Journal of Substance Abuse Treatment</i> , 2003, 24, 81-88.	2.8	51

#	ARTICLE	IF	CITATIONS
19	Do Mechanisms that Link Addiction Treatment Patients to Primary Care Influence Subsequent Utilization of Emergency and Hospital Care?. <i>Medical Care</i> , 2006, 44, 8-15.	2.4	51
20	Just call it "treatment". <i>Addiction Science & Clinical Practice</i> , 2012, 7, 10.	2.6	49
21	Medicaid Benefits For Addiction Treatment Expanded After Implementation Of The Affordable Care Act. <i>Health Affairs</i> , 2018, 37, 1216-1222.	5.2	42
22	Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109254.	3.2	40
23	Adoption of Evidence-Based Clinical Innovations. <i>Medical Care Research and Review</i> , 2014, 71, 43-60.	2.1	38
24	The Effect of Alcohol Abuse on the Health Status of Older Adults Seen in the Emergency Department. <i>American Journal of Drug and Alcohol Abuse</i> , 1999, 25, 529-542.	2.1	36
25	Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 45-48.	2.8	36
26	Medicaid coverage in substance use disorder treatment after the affordable care act. <i>Journal of Substance Abuse Treatment</i> , 2019, 102, 1-7.	2.8	35
27	Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. <i>Addiction</i> , 2017, 112, 1440-1450.	3.3	34
28	Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs. <i>American Journal of Public Health</i> , 2019, 109, 434-436.	2.7	34
29	Collaborative Behavioral Management for Drug-Involved Parolees: Rationale and Design of the Step'n Out Study. <i>Journal of Offender Rehabilitation</i> , 2008, 47, 290-318.	0.8	33
30	Predictors of Emergency Medical Services Utilization by Elders. <i>Academic Emergency Medicine</i> , 2003, 10, 52-58.	1.8	29
31	Predictors of follow-up health status in the Drug Abuse Treatment Outcome Study (DATOS). <i>Drug and Alcohol Dependence</i> , 2003, 69, 243-251.	3.2	28
32	Top Manager Effects on Buprenorphine Adoption in Outpatient Substance Abuse Treatment Programs. <i>Journal of Behavioral Health Services and Research</i> , 2010, 37, 322-337.	1.4	28
33	Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial. <i>Contemporary Clinical Trials</i> , 2015, 41, 110-117.	1.8	26
34	How ACA Repeal Would Worsen the Opioid Epidemic. <i>New England Journal of Medicine</i> , 2017, 376, e16.	27.0	24
35	Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108275.	2.8	20
36	Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 61-65.	2.8	19

#	ARTICLE	IF	CITATIONS
37	Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics. <i>Psychiatric Services</i> , 2020, 71, 35-42.	2.0	19
38	Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study. <i>Journal of Substance Abuse Treatment</i> , 2018, 87, 50-55.	2.8	17
39	More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. <i>Addiction Science & Clinical Practice</i> , 2017, 12, 29.	2.6	16
40	Opioid initiation and injection transition in rural northern New England: A mixed-methods approach. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108256.	3.2	14
41	Discrepancies in addressing overdose prevention through prescription monitoring programs. <i>Drug and Alcohol Dependence</i> , 2015, 153, 355-358.	3.2	13
42	Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109394.	3.2	12
43	Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol. <i>Addiction Science & Clinical Practice</i> , 2017, 12, 8.	2.6	11
44	Designated case managers as facilitators of medical and psychosocial service delivery in addiction treatment programs. <i>Journal of Behavioral Health Services and Research</i> , 2004, 31, 86-97.	1.4	10
45	Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. <i>Journal of Substance Abuse Treatment</i> , 2022, 138, 108746.	2.8	10
46	State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. <i>Psychiatric Services</i> , 2018, 69, 448-455.	2.0	9
47	Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 66-69.	2.8	9
48	Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. <i>Drug and Alcohol Dependence</i> , 2019, 194, 482-486.	3.2	9
49	Partnering with parents to improve outcomes for substance exposed newborns—a pilot program. <i>Journal of Perinatology</i> , 2020, 40, 1041-1049.	2.0	9
50	Benefit requirements for substance use disorder treatment in state health insurance exchanges. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 426-430.	2.1	8
51	The relationship of Medicaid expansion to psychiatric comorbidity care within substance use disorder treatment programs. <i>Journal of Substance Abuse Treatment</i> , 2019, 105, 44-50.	2.8	7
52	Linkages Between Patient-centered Medical Homes and Addiction Treatment Organizations. <i>Medical Care</i> , 2017, 55, 379-383.	2.4	5
53	Commitment and Capacity for Providing Evidence-Based Tobacco Treatment in Us Drug Treatment Facilities. <i>Substance Abuse</i> , 2017, 38, 35-39.	2.3	5
54	Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 66-72.	2.8	4

#	ARTICLE	IF	CITATIONS
55	Changes in State Technical Assistance Priorities and Block Grant Funds for Addiction After ACA Implementation. <i>American Journal of Public Health</i> , 2019, 109, 885-891.	2.7	4
56	Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. <i>Rhode Island Medical Journal</i> (2013), 2014, 97, 20-4.	0.2	4
57	Professional satisfaction experienced when caring for substance-abusing patients. <i>Journal of General Internal Medicine</i> , 2002, 17, 373-376.	2.6	3
58	Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 160-172.	1.3	2
59	Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 31-33.	2.8	1
60	Editorial: COVID-19 and its impact on SUD treatment. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108091.	2.8	1
61	Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. <i>Substance Abuse</i> , 2020, 42, 1-7.	2.3	1
62	Editorial: Health equity in substance use disorder treatment. <i>Journal of Substance Abuse Treatment</i> , 2020, 118, 108101.	2.8	0
63	New standards for a new era: Making JSAT better, not perfect. <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108366.	2.8	0